ProCE Banner Activity

CHRYSALIS: Updated Phase I Trial Results of Amivantamab in Advanced NSCLC With MET Exon 14 Skipping Mutations

Slideset Download
Conference Coverage
Preliminary results suggest that amivantamab antitumor activity is consistent with that of approved MET TKIs in patients with METex14-driven advanced NSCLC.

Released: June 10, 2022

Expiration: June 09, 2023

No longer available for credit.
Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.


Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab